Pharmaceutical compounding rules, summarised from primary sources posts 121–150
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Taking post #120 at face value and following it one step further.
Reframing pharmaceutical compounding rules slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Collapsed as off-topic by two members at trust level 3 or above
Import rules for personal quantities differ from commercial import rules and both differ by country. Establishing your own position is not something a forum can do for you.
The claim about pharmaceutical compounding rules upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Post #126 put the caveat in the right place and I want to underline it.
If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
Collapsed as off-topic by two members at trust level 3 or above
Post #128 is right about the mechanism and I think understates the practical bit.
Practical experience of pharmaceutical compounding rules, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Read the primary regulatory document rather than a summary of it. Summaries in this area lag by a year routinely and by longer occasionally.
Two sources, same conclusion, and I could not rule out that one copied the other.
Pharmaceutical compounding rules is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
I would call the community position on pharmaceutical compounding rules likely rather than established, and I would be comfortable defending that hedge.
I had written a reply contradicting post #130 and deleted it. Here is what survived.
Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.
Scoping that to what I have actually seen rather than what I have read.
Confirming post #133 from a second method, which matters more than confirming it from a second person.
Contradicting a claim in this subcategory is most useful when it comes with a link to the primary source and a date of access.
Import rules for personal quantities differ from commercial import rules and both differ by country. Establishing your own position is not something a forum can do for you.
Worth checking against a second source before it gets quoted onward.
The arithmetic in post #133 is right; the assumption feeding it is the part to check.
An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.
That is my reading. Someone else read the same page differently and was reasonable.
Clear enough that I do not think I have a follow-up, which is unusual.
Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.
Everything in post #138 holds. The case it does not cover is the one I have.
Summarising the pharmaceutical compounding rules thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Collapsed as off-topic by two members at trust level 3 or above
A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.
Answering the pharmaceutical compounding rules question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
Second this, and I would have said it less carefully.
Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.
Nothing above should be read as advice about what anyone else should do.
This follows post #143 rather than contradicting it.
My experience of pharmaceutical compounding rules contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Worth separating two things that post #144 runs together.
Reading back through the pharmaceutical compounding rules threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
What I can speak to on pharmaceutical compounding rules is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
The arithmetic in post #146 is right; the assumption feeding it is the part to check.
An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.
Genuinely open to being wrong about this one.
Read the primary regulatory document rather than a summary of it. Summaries in this area lag by a year routinely and by longer occasionally.
The part I am sure of is shorter than the part I have written.